ArticleArthritis research & therapy2026
Human MAGI1 expression in endothelial cells protects from the development of localized and systemic scleroderma in mice.
Article in Arthritis research & therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundSystemic sclerosis and localized scleroderma are rheumatoid fibrotic diseases characterized by altered blood vessel permeability and dysregulated angiogenesis. MAGI1 is an intracellular protein expressed at the epithelial and endothelial cell junction, regulating cell adhesion and epithelial/endothelial integrity. Endothelial cell MAGI1 regulates angiogenic function and blood flow. In the present study, we investigated the role of transgenic human MAGI1 in endothelial cells in animal models of localized scleroderma and systemic sclerosis.
methodsWild-type and human MAGI1-overexpressing endothelial cells in mice were challenged with sodium hypochlorite or bleomycin injections to induce sclerosis/scleroderma, mimicking the human disease. Conventional methods and automated software were employed to investigate the integrity of lung and skin tissue and quantify fibrosis. In vivo permeability and in vitro angiogenic models were employed to investigate the regulation of endothelial cell function.
resultsDermal thickening, lung tissue density, fibrotic foci development, and collagen accumulation induced by Bleomycin or sodium hypochlorite were significantly reduced in mice overexpressing human MAGI1 in endothelial cells relative to wild-type mice. Skin permeability and in vitro endothelial cell permeability were also reduced under MAGI1 overexpression. Furthermore, MAGI1 overexpression reduced the in vitro proangiogenic effects of VEGF-A, providing a putative mechanism of action.
conclusionsThe results indicate that endothelial cells expressing transgenic human MAGI1 attenuate tissue permeability and fibrotic responses in models of bleomycin- and sodium hypochlorite-induced scleroderma/sclerosis. MAGI1 overexpression blocks VEGF-A-induced permeability and angiogenesis in endothelial cells. Therefore, restoring endothelial cells could potentially alleviate VEGF-A-driven diseases such as localized scleroderma and systemic sclerosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.